Amyl Therapeutics: $9.6M Series A, 2 patent families, and a thin-but-real moat
Amyl Therapeutics holds 2 patent families: 2 granted and 0 published and pending. Filing began in 2019, with the most recent published filing dated 2020-06-18. The families appear in 2 patent offices: Europe and United States.Patent figures from Google Patents Public Data, reviewed 2026-09-14. Funding: $9.6M Series A, Mérieux Equity Partners, Sambrinvest and Smedvig, 2026-09-01.
Amyl Therapeutics is a preclinical stage biotechnology company.
The funding headline
Amyl Therapeutics raised $9.6M in a Series A, with Mérieux Equity Partners and Sambrinvest among its investors, announced 2026-09-01.
Behind that announcement is a patent position worth examining on its own terms.
Granted against pending
2 of 2 families are granted, or 100 percent.
A record weighted this way makes examination developments a subject in their own right.
The people on the filings
7 inventors are named across the portfolio.
Inventor names help organize an investigation. Ownership is determined by assignment records, not by who is listed.
The company it keeps
The same CPC groups drew University of California, Zhejiang University and Huazhong Agricultural University over the last five years.
A shared classification indicates a common field. It is a starting point for research, not a conclusion about competition.
Who has referenced the work
Patent records from Proclara Biosciences, Loyola Marymount Univ and Alzheon cite these filings.
A citation establishes a reference and nothing more. Its usefulness grows alongside other evidence.
What happens next
The current position is a baseline. What changes around it carries more information than the count does.
What happens next
Which new filings appear as the current applications publish?
Do the granted claims track the product the company is selling?
Which organizations begin filing or citing in the same areas?
Does the assignment record still name the operating entity?
Following those together can distinguish a passing resemblance from a subject deserving deeper investigation.
Common questions
How many patents does Amyl Therapeutics have?
Amyl Therapeutics holds 2 patent families as reviewed in 2026-09: 2 granted and 0 published and pending.
How many of Amyl Therapeutics's patents are granted?
2 of the 2 families are granted, or 100 percent. The remaining 0 are published and still under examination.
What technology do Amyl Therapeutics's patents cover?
Amyl Therapeutics's claims cluster in medicinal preparations (A61K) and peptides and antibodies (C07K). Recent filing titles include "general amyloid interaction motif (gaim)" and "polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal".
Where has Amyl Therapeutics filed patents?
Amyl Therapeutics's families appear in 2 patent offices: Europe and United States.
Which companies file patents in the same areas as Amyl Therapeutics?
The same CPC groups drew University of California, Zhejiang University, Huazhong Agricultural University and China Agricultural University over the last five years. Shared classification indicates a common technology field rather than direct competition.
Who cites Amyl Therapeutics's patents?
Patent records from Proclara Biosciences, Loyola Marymount Univ, Alzheon and Mount Saint Marys Univ cite Amyl Therapeutics's filings. A citation indicates a reference to the work, not evidence of commercial use.
Who invented Amyl Therapeutics's patents?
7 inventors are named across the portfolio. The most frequently named is Rajaraman Krishnan. Inventor names do not establish ownership, which is determined by assignment records.
GET IN TOUCH NOW!
OR SCHEDULE A MEETING
